Close

Ionis (IONS) Partner Biogen Reports Blow-Out Spinraza Sales - BMO Capital

July 25, 2017 7:50 AM EDT Send to a Friend
BMO Capital analyst Do Kim notes Ionis Pharmaceuticals (NASDAQ: IONS) partner Biogen reported 2Q17 Spinraza sales of $203mn, easily beating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login